To PRO or not to PRO? That’s not the question
The current pandemic has put enormous pressures on cancer care. The role of e-Health technologies in the management of cancer care is becoming more vital than ever.
Read more
HER2 and Herceptin®: A Look at the History
The discovery of the HER2 gene led to the development of Herceptin®: a targeted therapy that is widely used today for HER2+ breast cancer patients.
Read more
Chemobrain without having chemotherapy?
Cognitive decline (chemobrain) is usually only spoken about as being a side effect of chemotherapy, yet studies have shown that other treatments can cause chemobrain.
Read more
Digital health apps to transform cancer and dementia care
OWise for prostate cancer is currently under development. Read here to see OWise’s feature in The Herald and how the app hopes to benefit prostate cancer patients.
Read more
Cancer Related Fatigue – it’s not “just tiredness”
Cancer-related fatigue is a common and weakening side effects of cancer. People with cancer know what being tired normally feels like; this feeling of fatigue is different.
Read more
What are monoclonal antibodies?
There is a lot of terminology that comes with a breast cancer diagnosis. Explore how monoclonal antibodies such as Herceptin® work and how to recognise them!
Read more
OWise wins top NESTA Healthier Lives Data Fund Prize
Px Healthcare won £60,000 in funding from the Scottish Government to keep developing their products and scale them across Scotland.
Read more
NHS Lothian trials groundbreaking OWise cancer patient app
A version of OWise that is integrated into the hospital’s electronic health record system is being trialled at NHS Lothian in Scotland. Read here to see OWise’s feature in The National about this, and how it is benefitting patients and clinicians.
Read more
NICE exemplar
A case study example in the NICE evidence standard framework for digital health technologies.
Read more
OWise receives top prize in Scotland’s Cancer Innovation Challenge
OWise was one of the projects selected to win the finals and progress to phase two of the Cancer Innovation Challenge!
Read more
NHS approved
OWise is one in five cancer apps listed in the NHS app library.
Read more
CE-marked: Class I Medical Device
OWise was CE-marked to comply with the European regulatory standards for safety and usage on the 7th of May, 2014.
Read more
OWise breast cancer listed in the Top 25 of all health apps by IQVIA.
OWise breast cancer was listed in the Top 25 of all health apps by IQVIA.
Read more
NHS Innovation Accelerator
Anne joined the NHS Innovation Accelerator (NIA) from the Netherlands to develop OWise in 2015. The NIA is facilitating Anne’s … Continue reading “NHS Innovation Accelerator”
Read more
First place in the Digital Health Masterclass Challenge 2013
Px HealthCare won first place in the Digital Health Masterclass Challenge held by Janssen Healthcare Innovation and Johnson & Johnson Innovation.
Read more